|
|
||||||||
Eur J Cardiothorac Surg 2007;31:851-859. doi:10.1016/j.ejcts.2007.02.009
Copyright © 2007, European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved
Departments of Cardio-Thoracic Surgery, Cardiology, and Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands
Received 9 September 2006; received in revised form 5 January 2007; accepted 8 February 2007.
* Corresponding author. Address: Department of Cardio-Thoracic Surgery, Bd563, ErasmusMC, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands. Tel.: +31 10 4635413; fax: +31 10 4633993. (Email: j.j.m.takkenberg{at}erasmusmc.nl).
Objective: Whether allografts are the biological valve of choice for AVR in non-elderly patients remains a topic of debate. In this light we analyzed our ongoing prospective allograft AVR cohort and compared allograft durability with other biological aortic valve substitutes. Methods: Between April 1987 and October 2005, 336 patients underwent 346 allograft AVRs (95 subcoronary, 251 root replacement). Patient and perioperative characteristics, cumulative survival, freedom from reoperation, and valve-related events were analyzed. Using microsimulation, for adult patients, age-matched actual freedom from allograft reoperation was compared to porcine and pericardial bioprostheses. Results: Mean age was 45 years (range 1 month to 83 years); 72% were males. Etiology was mainly endocarditis 32% (active 22%), congenital 31%, degenerative 9%, and aneurysm/dissection 12%. Twenty-seven percent underwent prior cardiac surgery. Hospital mortality was 5.5% (N = 19). During follow-up (mean 7.4 years, maximum 18.5 years, 98% complete), 54 patients died; there were 57 valve-related reoperations (3 early technical, 11 non-structural, 39 structural valve deterioration (SVD), 4 endocarditis), 5 cerebrovascular accidents, 1 fatal bleeding, 8 endocarditis. Twelve-year cumulative survival was 71% (SE 3), freedom from reoperation for SVD 77% (SE 4); younger patient age was associated with increased SVD rates. Actual risk of allograft reoperation was comparable to porcine and pericardial bioprostheses in a simulated age-matched population. Conclusions: The use of allografts for AVR is associated with low occurrence rates of most valve-related events, but over time the risk of SVD increases, comparable to stented xenografts. It remains in our institute the preferred valve substitute only for patients with active aortic root endocarditis and for patients in whom anticoagulation should be avoided.
Key Words: Aortic valve replacement Allografts Prognosis Reoperation
This article has been cited by other articles:
![]() |
J. S. Borer and L. N. Girardi Repair of the congenitally bicuspid regurgitant aortic valve a strategic advance. J. Am. Coll. Cardiol., July 1, 2008; 52(1): 50 - 51. [Full Text] [PDF] |
||||
![]() |
M. Masuda, H. Kado, Y. Ando, A. Shiose, T. Nakano, K. Fukae, Y. Tanoue, and R. Tominaga Intermediate-term results after the aortic valve replacement using bileaflet mechanical prosthetic valve in children. Eur. J. Cardiothorac. Surg., July 1, 2008; 34(1): 42 - 47. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |